Accutar Biotechnology Receives FDA Fast Track Designation for AC699 in ER+ / HER2- Breast Cancer

Accutar Biotechnology receives FDA Fast Track designation for AC699 in ER+/HER2- breast cancer. AC699, an AI-enabled drug, targets ESR1-mutated advanced or metastatic breast cancer, showing a 50% objective response rate in Phase 1 trials.